Identification
- Generic Name
- Magnesium cation
- DrugBank Accession Number
- DB01378
- Background
Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Magnesium cation (DB01378)
- Weight
- Average: 24.305
Monoisotopic: 23.985041898 - Chemical Formula
- Mg
- Synonyms
- Magnesium ion
- Magnesium, ion(Mg2+)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Magnesium cation. Aclidinium The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Magnesium cation is combined with Alloin. Almasilate The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Almasilate. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image KALSIMAG-D3 EFERVESAN GRANUL ICEREN SASE, 30 ADET Magnesium cation (493.37 mg) + Calcium carbonate (2500 mg) + Cholecalciferol (880 IU) Granule, effervescent Oral BERKO İLAÇ VE KİMYA SAN. A.Ş. 2020-08-14 Not applicable Turkey 
KALSIMAG-D3 EFERVESAN GRANUL ICEREN SASE, 40 ADET Magnesium cation (493.37 mg) + Calcium carbonate (2500 mg) + Cholecalciferol (880 IU) Granule, effervescent Oral BERKO İLAÇ VE KİMYA SAN. A.Ş. 2017-08-11 Not applicable Turkey MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 10 ADET Magnesium cation (342 mg) + Magnesium carbonate (670 mg) Granule Oral BİLİM İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 20 ADET Magnesium cation (342 mg) + Magnesium carbonate (670 mg) Granule Oral BİLİM İLAÇ SAN. VE TİC. A.Ş. 2018-09-12 Not applicable Turkey MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 30 ADET Magnesium cation (342 mg) + Magnesium carbonate (670 mg) Granule Oral BİLİM İLAÇ SAN. VE TİC. A.Ş. 2018-09-12 Not applicable Turkey
Categories
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Calculi Dissolution Agent
- Increased Large Intestinal Motility
- Inhibition Large Intestine Fluid/Electrolyte Absorption
- Inhibition Small Intestine Fluid/Electrolyte Absorption
- Laxatives
- Magnesium Ion Exchange Activity
- Minerals
- Osmotic Activity
- Osmotic Laxatives
- Polyvalent cation containing laxatives, antacids, oral supplements
- Stimulation Large Intestine Fluid/Electrolyte Secretion
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous alkaline earth metal compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous alkaline earth metal compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous alkaline earth metal
- Molecular Framework
- Not Available
- External Descriptors
- monoatomic dication, divalent metal cation, magnesium cation (CHEBI:18420) / a cation (MG+2)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- T6V3LHY838
- CAS number
- 22537-22-0
- InChI Key
- JLVVSXFLKOJNIY-UHFFFAOYSA-N
- InChI
- InChI=1S/Mg/q+2
- IUPAC Name
- magnesium(2+) ion
- SMILES
- [Mg++]
References
- Synthesis Reference
David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, "Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet." U.S. Patent US4151013, issued 0000.
US4151013- General References
- Not Available
- External Links
- PDB Entries
- 101d / 109d / 119d / 121p / 13pk / 146d / 150d / 159d / 184d / 1a05 … show 22437 more
- MSDS
- Download (73.4 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- American Regent
- American Therapeutics Medicines Inc.
- Bioniche Pharma
- Claris Lifesciences Inc.
- DSM Corp.
- Luitpold Pharmaceuticals Inc.
- Mallinckrodt Baker Inc.
- McGuff Co. Inc.
- Merit Pharmaceuticals
- Pekana Naturheilmittel GmbH
- Torrance Co.
- United Guardian Inc.
- Dosage Forms
Form Route Strength Tablet, effervescent 365 mg Granule, effervescent Oral Tablet 365 mg Granule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 651 °C PhysProp boiling point (°C) 1100 °C PhysProp - Predicted Properties
Property Value Source logP -0.57 Chemaxon pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8382 Blood Brain Barrier + 0.9708 Caco-2 permeable + 0.7056 P-glycoprotein substrate Non-substrate 0.8831 P-glycoprotein inhibitor I Non-inhibitor 0.9869 P-glycoprotein inhibitor II Non-inhibitor 0.9855 Renal organic cation transporter Non-inhibitor 0.9176 CYP450 2C9 substrate Non-substrate 0.8465 CYP450 2D6 substrate Non-substrate 0.823 CYP450 3A4 substrate Non-substrate 0.8094 CYP450 1A2 substrate Non-inhibitor 0.8824 CYP450 2C9 inhibitor Non-inhibitor 0.9221 CYP450 2D6 inhibitor Non-inhibitor 0.9555 CYP450 2C19 inhibitor Non-inhibitor 0.9469 CYP450 3A4 inhibitor Non-inhibitor 0.9846 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9015 Ames test Non AMES toxic 0.9663 Carcinogenicity Carcinogens 0.6381 Biodegradation Ready biodegradable 0.9031 Rat acute toxicity 2.0881 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9462 hERG inhibition (predictor II) Non-inhibitor 0.9716
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [Article]
- Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [Article]
- Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [Article]
- Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [Article]
Drug created at July 06, 2007 20:30 / Updated at February 20, 2024 23:55